OOIR: Observatory of International Research

Papers

(The TQCC of Expert Review of Clinical Pharmacology is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Strategies for lowering lipoprotein(a): a spotlight on novel pharmacological treatments	66
Personalizing tamoxifen therapy in adjuvant therapy: a brief summary of the ongoing discussion	44
Renin angiotensin aldosterone inhibitors in the treatment of proteinuria in children with congenital anomalies of the kidney and urinary tract: more evidence needed	40
Reducing the risk of death – a possible outcome in COPD patients	36
Clinical pharmacology of antiplatelet drugs	32
Sodium-glucose cotransporter 2 inhibitors in frail, older people with type 2 diabetes and heart failure: do we have enough evidence to confidently support the use?	32
Why is diagnosis, investigation, and improved management of kidney stone disease important? Non-pharmacological and pharmacological treatments for nephrolithiasis	32
Therapeutic drug monitoring of antiretroviral therapy: current progresses and future directions	32
Risk of new onset diabetes mellitus with pitavastatin as compared to atorvastatin and rosuvastatin: a systematic review and meta-analysis	31
Effects of the augmentation with quetiapine or olanzapine on the metabolism of duloxetine: a retrospective analysis	30
Prostate cancer and novel pharmacological treatment options–what’s new for 2022?	30
Pharmacological and clinical profile of ravulizumab 100 mg/mL formulation for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome	27
Management of polypharmacy through deprescribing in older patients: a review of the role of AI tools	27
A review of current and emerging therapies in breast cancer: implications for older adults	26
Sparsentan: a dual endothelin and angiotensin II receptor antagonist approved for IgA nephropathy	25
JAK inhibitors in dermatology: the road travelled and path ahead, a narrative review	25
Practical considerations and emerging approaches for the management of vasomotor and sexual symptoms in breast cancer patients on endocrine therapies	25
What is the potential for abuse of lisdexamfetamine in adults? A preclinical and clinical literature review and expert opinion	25
Amylin analogs for the treatment of obesity without diabetes: present and future	23
Fetal safety of medications used in treating infertility	23
Clinical efficacy and safety of topical difamilast in the treatment of patients with atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials	22
Role of tenecteplase in ischemic stroke after 4.5 hours: an evaluation of the TRACE-III trial	22
Treatment management for rosacea: current pharmacological and non-pharmacological options	21
Brimonidine tartrate ophthalmic solution 0.025% for redness relief: an overview of safety and efficacy	21
Broadening access to tenofovir alafenamide for the treatment and prevention of HIV-1 infection	21

Cannabidiol drug interaction considerations for prescribers and pharmacists	19
Dostarlimab for the treatment of advanced endometrial cancer	19
The pharmacotherapeutics of sarcoidosis	19
Reply to: The risk for genito-urinary infections with sodium-glucose cotransporter-2 inhibitors: duration rather than dose matter?	18
Complications related to oral corticosteroid use in asthma patients: a retrospective cohort study	18
The thiazide-like diuretic chlorthalidone as an alternative evidence-based therapy for resistant hypertension in patients with stage 4 chronic kidney disease	18
Recent pharmacological approaches for the treatment of renal cell carcinoma	17
Pharmacogenetics-based population pharmacokinetic analysis for dose optimization of ritonavir-boosted atazanavir in Thai adult HIV-infected patients	17
Intestinal microbiome and epilepsy: a new therapeutic approach?	16
Pharmacological strategies for the management of the antisocial personality disorder	16
Nirmatrelvir/Ritonavir and molnupiravir: an update on COVID-19 antivirals in the Omicron era	16
Voclosporin: a novel calcineurin inhibitor for the treatment of lupus nephritis	15
Pediatric attention deficit hyperactivity disorder (ADHD): 2022 updates on pharmacological management	15
OPTIMA-ID: development and validation of a medicine optimization tool for older adults with intellectual disability	15
Nicotine e-cigarettes for smoking cessation: a clinical pharmacology perspective	15
Melflufen for the treatment of multiple myeloma	15
A profile of azetukalner for the treatment of epilepsy: from pharmacology to potential for therapy	14
Effect of laparoscopic sleeve gastrectomy on drug pharmacokinetics	14
Population pharmacokinetic modeling and exposure-response analysis of anrikefon: insights and implications in clinical analgesia	14
Drug-drug interactions associated with FLT3 inhibitors for acute myeloblastic leukemia: current landscape	13
Hydroxyurea in the sickle cell disease modern era	13
Current status and prospects of IL-6–targeting therapy	13
Association between sodium-glucose cotransporter 2 inhibitors and eye disorders: a systematic review and meta-analysis	13
Clozapine for older adults with severe mental illness: a systematic review and expert recommendations for clinical practice	13
Real-world clinical effectiveness of once-weekly semaglutide in patients with type 2 diabetes: a systematic literature review	12
Early response is a strong predictor of the long-term response in psoriasis patients receiving risankizumab or guselkumab in the real-world: a retrospective analysis	12
Methenamine Hippurate in UTI management: a reemerging pharmacological strategy	12
Methotrexate polyglutamates	12
FLOT vs CROSS in localized esophageal adenocarcinoma: what is the current best strategy?	12
A narrative review of non-racemic amisulpride (SEP-4199) for treatment of depressive symptoms in bipolar disorder and LB-102 for treatment of schizophrenia	12
Clinical pharmacology of SGLT-2 inhibitors in heart failure	12
Pharmacogenomics – a minor rather than major force in clinical medicine	11
Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF)	11
Physiologically-based pharmacokinetic modeling to predict the exposure and provide dosage regimens of adalimumab in patients with juvenile idiopathic arthritis	11
The nocebo phenomenon in the COVID-19 pandemic: a nocebodemic effect	11
Designer benzodiazepines: an update	11
An observational study of safety and clinical outcome measures across patient groups in the United Kingdom Medical Cannabis Registry	11
Revisiting the association between sodium-glucose cotransporter-2 inhibitors and the risk of neoplasm in patients with type 2 diabetes: new insights from an updated systematic review and meta-analysis	11
A systematic review and meta-analysis of users versus non-users: unveiling the influence of proton pump inhibitors on capecitabine efficacy in colorectal cancer	11
Antimicrobial safety considerations in critically ill patients: part II: focused on anti-microbial toxicities	11
Pharmacotherapy for previously treated gastric cancer patients: current options and future developments	11
Efficacy and safety of tislelizumab for malignant solid tumor: a systematic review and meta-analysis of phase III randomized trials	11
Risk factors for a broken heart: understanding drug-induced causes for Takotsubo syndrome and pharmacological treatment options	11
Revolutionizing diabetes care: unveiling tirzepatide’s potential in glycemic control and beyond	10
Efficacy and safety of dupilumab in chronic rhinosinusitis with nasal polyps: a systematic review and meta-analysis	10
Golimumab retention in patients with psoriatic arthritis and axial spondyloarthritis: evidence from up to a decade of follow-up	10
Pharmacokinetic interaction of quetiapine and lamotrigine – victim and perpetrator?	10
Encouraging appropriate use of proton pump inhibitors: existing initiatives and proposals for the future	10
Is therapeutic drug monitoring a dancing partner for TNF-α inhibitors in real-world practice? Answers from an updated systematic review and meta-analysis	10
Genito-urinary infectious adverse events related to sodium glucose cotransporter-2 inhibitors: a network meta-analysis and meta-regression	10

Phosphatidylinositol 3 kinase inhibitor-related pneumonitis: a systematic review and meta-analysis	10
Optimization of secukinumab dose regimens in patients with moderate-to-severe plaque psoriasis via exposure-response modeling	10
Signal mining study of severe cutaneous adverse events of valaciclovir or acyclovir based on the FAERS database	10
TYK2 as a novel therapeutic target in psoriasis	10
Pharmacological and safety profile of a prolonged-release lanreotide formulation in acromegaly	9
Interstitial lung disease associated with anti-HER2 anti-body drug conjugates: results from clinical trials and the WHO's pharmacovigilance database	9
Psychedelic drugs for the treatment of substance use disorders	9
Clinical pharmacology of siRNA therapeutics: current status and future prospects	9
Hormonal contraception, past, present, and future part 1: the early path – facts, stories, and controversies	9
Dasiglucagon for treating severe hypoglycemia in patients with diabetes	9
Gender differences in new hypoglycemic drug effects on renal outcomes: a systematic review	9
Biomarker discovery in acetaminophen hepatotoxicity: leveraging single-cell transcriptomics and mechanistic insight	9
Clozapine for treatment refractory catatonia in individuals with autism spectrum disorder: a retrospective chart review study	9
Statin-related neurocognitive disorder: a real-world pharmacovigilance study based on the FDA adverse event reporting system	8
Keeping up with venetoclax for leukemic malignancies: key findings, optimal regimens, and clinical considerations	8
Practical challenges and considerations in adopting biosimilars in oncology clinical practice within a large healthcare system	8
The future of pharmacology education: The Veterinary Educators in Pharmacology Special Interest Group (VEPSIG)	8
Profile of estetrol, a promising native estrogen for oral contraception and the relief of climacteric symptoms of menopause	8
Reliance is key to effective access and oversight of medical products in case of public health emergencies	8
Advances in pharmacokinetic-pharmacodynamic modelling for pediatric drug development: extrapolations and exposure-response analyses	8
Adverse clinical outcomes associated with drug-related hospitalizations in people with dementia	8
Clinical outcomes of oral anticoagulant discontinuation in atrial fibrillation: a systematic review and meta-analysis	8
The pharmacotherapeutic options in patients with catecholamine-resistant vasodilatory shock	8
Current understanding of the etiology of cyclic vomiting syndrome and therapeutic strategies in its management	8
Antimicrobial safety considerations in critically ill patients: part I: focused on acute kidney injury	8
Opioid use disorder in pediatric populations: considerations for perioperative pain management and precision opioid analgesia	8
Pharmacological treatment for transforming growth factor beta induced corneal dystrophies: what is the way forward?	8
Considerations when prescribing opioid agonist therapies for people living with HIV	7
Availability and evaluation of medication management resources for carers of people with dementia: a scoping review with an environmental scan	7
Genotype-guided pharmacotherapy: the challenges of integrating pharmacogenomic testing into routine healthcare with a focus on experiences at a single site	7
Optimizing outcomes and managing adverse events in locally advanced or metastatic urothelial cancer: a clinical pharmacology perspective	7
Extending the ambit of SGLT2 inhibitors beyond diabetes: a review of clinical and preclinical studies on non-diabetic kidney disease	7
Treatment and prevention of influenza in geriatric patients	7
The impact of pregnancy-related hormonal and physiological changes on antiseizure medications: expert perspective	7
Effects of single-nucleotide polymorphism on the pharmacokinetics and pharmacodynamics of metformin	7
Comparing the renal outcomes in patients with atrial fibrillation receiving different oral anticoagulants	7
Pharmacology considerations for managing pregnancy in women with systemic lupus erythematosus	7
Intravitreal immunotherapy in non-infectious uveitis: an update	7
Impact of SGLT2 inhibitors on the kidney in people with type 2 diabetes and severely increased albuminuria	7
Implementing pharmacogenetics in clinical trials: considerations about current methodological, ethical, and regulatory challenges	7
Novel and emerging treatment strategies for lupus nephritis	7
Quantitative effects of sodium-glucose cotransporter-2 inhibitors on liver functions in patients with nonalcoholic fatty liver disease	7
Detrimental impact of gastric acid suppressants on vascular endothelial growth factor receptor tyrosine kinase inhibitors efficacy: evidence from a systematic review and meta-analysis	7
Intraperitoneal therapy for gastric cancer peritoneal carcinomatosis	7
The orexin system and alcohol use disorder: bridging the gap between preclinical and clinical research	7
Perspectives on deprescribing in older people with type 2 diabetes and/or cardiovascular conditions: challenges from healthcare provider, patient and caregiver perspective, and interventions to suppor	7
The changes of IgE levels in type 2 inflammatory diseases after treatment of dupilumab: a systematic review and meta-analysis	7
Next-generation sequencing in pharmacogenomics – fit for clinical decision support?	7
Biosimilar development and review process in the BRICS-TM countries: Proposal for a standardized model to improve regulatory performance	7